Treg/Th17在慢性阻塞性肺疾病合并肺癌中的相关研究进展

Research Progress of Treg/Th17 in the Treatment of Chronic Obstructive Pulmonary Disease with Lung Cancer

慢性阻塞性肺疾病(chronic obstructive pulmonary disease,COPD)和肺癌为全球性高发病率、高死亡率疾病,严重增加社会经济负担。烟雾暴露、遗传易感性和慢性炎症等是二者发病的共同易感因素。目前异常炎症免疫反应在两种疾病的发生、发展中均有作用,在免疫应答过程中逐渐产生有利于血管生成和免疫抑制的肿瘤微环境(tumor microenvironment,TME),最终使肿瘤细胞发生免疫逃逸,导致肿瘤形成。本文就COPD合并肺癌的现状以及异常免疫应答尤其是Treg/Th17与其发生、发展关系方面做一个简要综述。

Chronic obstructive pulmonary disease(COPD) and lung cancer are global high incidence and high mortality diseases,which seriously increase the socio-economic burden.Smoke exposure,genetic susceptibility and chronic inflammation are common susceptible factors.At present,abnormal inflammatory immune response plays an important role in the occurrence and development of the two diseases.In the process of immune response,tumor microenvironment(TME) is gradually produced,which is beneficial to angiogenesis and immunosuppression,and finally leads to immune escape of tumor cells,leading to tumor formation.In this paper,the present situation of COPD complicated with lung cancer and the relationship between abnormal immune response,especially Treg/Th17,and its occurrence and development are briefly reviewed.